Pulmonary surfactant biogenesis blockage mediated polyhexamethylene guanidine disinfectant induced pulmonary fibrosis.

J Hazard Mater

Clinical Medical Research Center for Women and Children Diseases, Shandong Provincial Maternal and Child Health Care Hospital Affiliated to Qingdao University, Jinan 250001, China; Department of Environmental and Occupational Health, School of Public Health, Qingdao University, Qingdao 266071, China. Electronic address:

Published: December 2024

The widespread use of disinfectants and inhalation exposure to aerosolized forms is closely associated with adverse health effects on the respiratory system and pulmonary fibrosis, but the mechanism remains unclear. Here, we investigated the time-course pulmonary fibrosis effects of polyhexamethylene guanidine (PHMG) disinfectant inhalation exposure and elucidated its underlying mechanism. Specifically, scRNA-seq analysis revealed an initial increase in epithelial cell numbers after 4 weeks of PHMG exposure during induced pulmonary fibrosis, followed by a subsequent decrease after 8 weeks of exposure. Mechanistically, PHMG disrupted autophagic flux leading to intracellular accumulation and blocked pulmonary surfactant biogenesis in alveolar type II epithelial (AT2) cells both in vitro and in vivo. Furthermore, intervention studies using metformin confirmed that autophagy dysfunction mediated the blockage of pulmonary surfactant biogenesis in AT2 cells, playing a pivotal role in PHMG-induced pulmonary fibrosis. Our elucidation of these toxicological mechanisms provides valuable insights into the pathogenesis of pulmonary fibrosis triggered by environmental PHMG exposure, thereby offering a promising therapeutic target for mitigating and treating PHMG-associated pulmonary fibrosis.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhazmat.2024.136307DOI Listing

Publication Analysis

Top Keywords

pulmonary fibrosis
28
pulmonary surfactant
12
surfactant biogenesis
12
pulmonary
10
polyhexamethylene guanidine
8
induced pulmonary
8
inhalation exposure
8
phmg exposure
8
at2 cells
8
fibrosis
7

Similar Publications

Tobramycin nanoformulation for chronic pulmonary infections: From drug product definition to scale-up for preclinical evaluation.

Int J Pharm

January 2025

CIDETEC, Basque Research and Technology Alliance (BRTA), Parque Científico y Tecnológico de Gipuzkoa, Donostia-San Sebastián, Spain; Kusudama Therapeutics SA, Parque Científico y Tecnológico de Gipuzkoa, Donostia-San Sebastián, Spain; Biogipuzkoa Health Research Institute, Group of Innovation, 20014 San Sebastian, Spain.

Cystic fibrosis (CF) is characterized by abnormal mucus hydration due to a defective CF Transmembrane Regulator (CFTR) protein, leading to the production of difficult-to-clear mucus. This causes airflow obstruction, recurrent infections, and respiratory complications. Chronic lung infections are the leading cause of death for CF patients and inhaled tobramycin is the first-in-line antibiotic treatment against these infections, mainly caused by Pseudomonas aeruginosa in adult patients.

View Article and Find Full Text PDF

This paper presents a comprehensive review of the current literature, clinical trials, and products approved for the delivery of antibiotics to the lungs. While there are many literature reports describing potential delivery systems, few of these have translated into marketed products. Key challenges remaining are the high doses required and, for powder formulations, the ability of the inhaler and powder combination to deliver the dose to the correct portion of the respiratory tract for maximum effect.

View Article and Find Full Text PDF

The Importance of Lung Innate Immunity During Health and Disease.

Pathogens

January 2025

Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan.

The lung is a vital organ for the body as the main source of oxygen input. Importantly, it is also an internal organ that has direct contact with the outside world. Innate immunity is a vital protective system in various organs, whereas, in the case of the lung, it helps maintain a healthy, functioning cellular and molecular environment and prevents any overt damage caused by pathogens or other inflammatory processes.

View Article and Find Full Text PDF

: Long-term lung sequelae in severe COVID-19 survivors, as well as their treatment, are poorly described in the current literature. : To investigate lung fibrotic sequelae in survivors of severe/critical COVID-19 pneumonia and their fate according to a "non-interventional" approach. : Prospective study of the above COVID-19 survivors after hospital discharge from March 2020 to October 2022.

View Article and Find Full Text PDF

Background: Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease with a median survival of 3-5 years. Antifibrotic therapies like pirfenidone and nintedanib slow progression, but the outcomes vary. Gender may influence disease presentation, progression, and response to treatment.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!